New Recruiting Trial: A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

WHY IT MATTERS

This trial is now recruiting patients and uses genetic testing to personalize belinostat dosing, which could help predict who will tolerate the drug better and reduce serious side effects.

Researchers are testing a cancer drug called belinostat to see how it works in people's bodies and what side effects it causes. The study is special because it looks at a genetic test (UGT1A1) that affects how people process this drug, so doctors can figure out the right dose for each person based on their genes.

NCT ID: NCT06406465 Title: A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity Status: RECRUITING Phase: PHASE2 Sponsor: National Cancer Institute (NCI) Start date: 2026-05-18 URL: https://clinicaltrials.gov/study/NCT06406465 Source: UniteRare clinical trials database